Enzyme‐mediated synthesis of Molnupiravir: paving the way for the application of biocatalysis in pharmaceutical industry

  1. Cruz, Guillermo 1
  2. Acosta, Javier 1
  3. Del Arco, Jon 1
  4. Clemente‐Suarez, Vicente Javier 12
  5. Deroncele, Víctor 3
  6. Fernández‐Lucas, Jesús 12
  1. 1 Universidad Europea de Madrid
    info

    Universidad Europea de Madrid

    Madrid, España

    ROR https://ror.org/04dp46240

  2. 2 Universidad de la Costa
    info

    Universidad de la Costa

    Barranquilla, Colombia

    ROR https://ror.org/01v5nhr20

  3. 3 Selabtec Sciences C\ Àlvarez de Castro, 63 08100 Mollet del Vallès Spain
Mostra les afiliacions +
Revista:
ChemCatChem

ISSN: 1867-3880,  1867-3899

Any de publicació: 2022

Tipus: Article

DOI: 10.1002/CCTC.202200140 GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: ChemCatChem

Resum

Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses for Molnupiravir synthesis. This concept paper aims to review the most relevant milestones that have guided important developments in the enzyme-mediated synthesis of Molnupiravir, including detailed comments on the advantages and drawbacks of the different synthetic routes. Finally, based on a personal perspective, new greener processes for Molnupiravir manufacturing are proposed and discussed.

€ Mostra el finançament

Informació de finançament

Finançadors

Referències bibliogràfiques

  • 10.1038/nrd4010
  • 10.1021/cr900028p
  • 10.1002/asia.201900841
  • Cox R. M., (2021), Nat. Microbiol., 6, pp. 1, 10.1038/s41564-020-00847-y
  • 10.1002/9783527812103
  • 10.2174/138527208783743723
  • 10.1016/j.molcatb.2016.08.015
  • 10.1007/s00253-015-6642-x
  • Del Arco J., (2017), Curr. Pharm. Des., 23, pp. 6898
  • Kaspar F., (2020), Green Chem., 23, pp. 37, 10.1039/D0GC02665D
  • 10.1007/s00253-018-9242-8
  • 10.1038/s41564-020-00835-2
  • 10.1038/s41594-021-00651-0
  • 10.1016/j.jbc.2021.100867
  • Syed Y. Y., (2022), Drugs, 82, pp. 455, 10.1007/s40265-022-01684-5
  • Whitley R., (2022), N. Engl. J. Med., 386, pp. 592, 10.1056/NEJMe2117814
  • G. R. Painter G. R. Bluemling M. G. Natchus D. Guthrie WO2019113462 A1 2019;
  • G. R. Painter D. Perryman G. R. Bluemling WO2019173602 2019.
  • 10.1002/ejoc.202001340
  • Hu T., (2022), Org. Process Res. Dev., 2, pp. 358, 10.1021/acs.oprd.1c00419
  • 10.1039/D0CC05944G
  • 10.1055/a-1275-2848
  • 10.1021/acsomega.1c00772
  • 10.1021/acs.oprd.1c00033
  • 10.1021/acscentsci.1c00608
  • Jhulki I., (2021), ACS Cent. Sci., 7, pp. 1963, 10.1021/acscentsci.1c01356
  • Simić S., (2021), Chem. Rev., 122, pp. 1052, 10.1021/acs.chemrev.1c00574
  • 10.1186/1860-5397-2-3
  • 10.1021/jacs.1c11048
  • Mullin R., (2021), C&EN Global Enterprise, 99, pp. 19, 10.1021/cen-09906-buscon14
  • 10.1016/j.jbiosc.2017.01.005
  • 10.1016/j.jbiosc.2017.07.016
  • 10.2174/138527206777697995
  • Acosta J., (2020), Front. Bioeng. Biotechnol., 8, pp. 593, 10.3389/fbioe.2020.00593
  • 10.1002/cbic.201900397
  • 10.1128/AEM.07605-11
  • 10.1016/j.foodchem.2017.05.136
  • 10.1016/j.biortech.2020.124547
  • 10.1016/j.biortech.2021.125649
  • 10.3390/catal9040355
  • 10.1002/cpz1.347
  • 10.1016/j.jbiotec.2010.11.013
  • 10.1016/j.ijbiomac.2021.09.164
  • 10.1002/cbic.202000679
  • 10.1016/j.bbapap.2019.140304
  • 10.1016/j.biortech.2020.123258
  • Rivero C. W., (2021), Biomol. Eng., 11, pp. 657
  • 10.1002/adsc.200404019